Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Guido Tavazzi, Carlo Pellegrini, Marco Maurelli, Mirko Belliato, Fabio Sciutti, Andrea Bottazzi, Paola Alessandra Sepe, Tullia Resasco, Rita Camporotondo, Raffaele Bruno, Fausto Baldanti, Stefania Paolucci, Stefano Pelenghi, Giorgio Antonio Iotti, Francesco Mojoli, Eloisa Arbustini, Guido Tavazzi, Carlo Pellegrini, Marco Maurelli, Mirko Belliato, Fabio Sciutti, Andrea Bottazzi, Paola Alessandra Sepe, Tullia Resasco, Rita Camporotondo, Raffaele Bruno, Fausto Baldanti, Stefania Paolucci, Stefano Pelenghi, Giorgio Antonio Iotti, Francesco Mojoli, Eloisa Arbustini

Abstract

We describe the first case of acute cardiac injury directly linked to myocardial localization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a 69-year-old patient with flu-like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock. The patient was successfully treated with venous-arterial extracorporeal membrane oxygenation (ECMO) and mechanical ventilation. Cardiac function fully recovered in 5 days and ECMO was removed. Endomyocardial biopsy demonstrated low-grade myocardial inflammation and viral particles in the myocardium suggesting either a viraemic phase or, alternatively, infected macrophage migration from the lung.

Keywords: Cardiac injury; Cardiogenic shock; Coronavirus; Extracorporeal membrane oxygenation; Myocardial inflammation; SARS-CoV-2.

© 2020 European Society of Cardiology.

Figures

Figure 1
Figure 1
Light microscopy immunostaining of the inflammatory infiltrate. (A,B) Low‐ and high‐power views of endomyocardial biopsy, with sparse CD45RO positive interstitial cells. (C,D) Large, vacuolated macrophages immunostained with anti‐CD68 antibodies. (E) Ultrastructural morphology of a large and cytopathic macrophage. (A–D: the bar scale is in the left low corner of each panel. E: the bar scale is in the right low corner of the panel and corresponds to 2 μm).
Figure 2
Figure 2
Examples of small groups of viral particles (A and B; panel C shows a higher magnification of one of the viral particles squared in dashed red box of panel B) or single particles (D–F) observed within the interstitial cells of the myocardium of the patient. The red arrows indicate the most typical and easy‐to‐recognize viral particles, whose size varies from about 70 nm to 120 nm (see the white bars in the panels). Morphology also shows small differences with more or less prominent spikes of the viral crown. The morphology may also show viral particle disruption (E, green arrow) or attenuation of spikes of the crown (D and F), or viral particles in budding attitude (F). (Bar scale: A and B, 200 nm; C, 50 nm; D, 100 nm; E, 100 nm; F, 50 nm).
Figure 3
Figure 3
Electron micrograph showing a cytopathic interstitial inflammatory cell (A) that contains viral particles (some of them are magnified in panel B that corresponds to the yellow squared area of panel A). The interstitial cell is in close contact with the adjacent cardiac myocyte (left). The viral particles show diameter variability in the range of 70–120 nm. Although the inflammatory cell and myocyte are closely adjacent, no viral particles are observed in the myocyte.

References

    1. Huang C, Wang Y, Li X, Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069.
    1. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID‐19 in China. Clin Res Cardiol 2020;109:531–538.
    1. Madjid M, Safavi‐Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020. Mar 27. 10.1001/jamacardio.2020.1286 [Epub ahead of print].
    1. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID‐19). JAMA Cardiol 2020. Mar 27. 10.1001/jamacardio.2020.1096 [Epub ahead of print].
    1. Alsaad KO, Hajeer AH, Al Balwi M, Al Moaiqel M, Al Oudah N, Al Ajlan A, AlJohani S, Alsolamy S, Gmati GE, Balkhy H, Al‐Jahdali HH, Baharoon SA, Arabi YM. Histopathology of Middle East respiratory syndrome coronovirus (MERS‐CoV) infection – clinicopathological and ultrastructural study. Histopathology 2018;72:516–524.
    1. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY; SARS Study Group . Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319–1325.
    1. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS‐CoV‐2 in different types of clinical specimens. JAMA 2020;323:1843–1844.
    1. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation 2020;141:e69–e92.
    1. van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline . Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017;136:e232–e268.
    1. Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, Botta L, Milazzo F, Actis Dato G, Casabona R, Casali G, Musumeci F, De Bonis M, Zangrillo A, Alfieri O, Pellegrini C, Mazzola S, Coletti G, Vizzardi E, Bianco R, Gerosa G, Massetti M, Caldaroni F, Pilato E, Pacini D, Di Bartolomeo R, Marinelli G, Sponga S, Livi U, Mauro R, Mariscalco G, Beghi C, Miceli A, Glauber M, Pappalardo F, Russo CF; GIROC Investigators . Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5‐year multi‐institutional experience. Ann Thorac Surg 2016;101:919–926.
    1. MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID‐19: the potential role of extracorporeal membrane oxygenation. JAMA 2020. Feb 19. 10.1001/jama.2020.2342 [Epub ahead of print].
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid‐19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
    1. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, Jain SS, Burkhoff D, Kumaraiah D, Rabbani L, Schwartz A, Uriel N. Coronavirus disease 2019 (COVID‐19) and cardiovascular disease. Circulation 2020. Mar 21. 10.1161/CIRCULATIONAHA.120.046941 [Epub ahead of print].
    1. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM. Interleukin‐1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016;44:275–281.

Source: PubMed

3
Prenumerera